Sichuan Huiyang Life Science and Technology Corporation Report issue

For profit Phase 2
Founded: Chengdu China (1997)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2013
NCT02387307
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Sichuan Huiyang Life Science and Technology Corporation

Active Ingredients

Drugs in Phase 2 Trials (1)

rsifn-co (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Carcinoma, Hepatocellular (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Carcinoma, Renal Cell (Phase 1)

Colonic Neoplasms (Phase 1)

Melanoma (Phase 1)

Neuroendocrine Tumors (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 1